Cardiovascular disease is a major cause of morbidity and is the leading cause of death in women and men in Western societies.
Acute Coronary Syndrome
There are pathophysiological differences in the causes of acute coronary syndrome (ACS) with respect to sex. In men, there is typically rupture of a thin-capped atheromatous plaque which triggers thrombosis. Women are more likely to develop thrombosis caused by endothelial erosion. 3 However, there is no evidence to suggest that this difference in pathophysiology should affect the treatment offered to patients. This is different to ACS caused by spontaneous coronary artery dissection (SCAD) which is significantly more likely to occur in women who account for 90% of patients and may be best managed medically. 4 Despite advancements in the management of ACS, various studies have shown a clear disparity in the clinical outcomes between men and women, with women having worse outcomes. [5] [6] [7] [8] [9] [10] Women are more likely to present with atypical symptoms, have delays in the administration of treatment and therefore have longer ischaemic times. 11 There is also evidence to suggest that women with ACS are less likely to receive evidence-based treatments and less likely to undergo cardiac catheterisation and revascularisation. [5] [6] [7] 9, [12] [13] [14] [15] [16] [17] [18] [19] Table 1 demonstrates the in-hospital mortality according to sex in several ACS studies. The proportion of female patients in the studies ranged from 27-41%. The unadjusted mortality is significantly higher in women, although appears less so once adjusted for confounders. 12, 16 A large UK study evaluating the treatment of patients with ACS with respect to sex has been published this year. 20 Women (n=238,489) comprised 34.5% of the study and were older (76.7 years versus 67.1 years) and less likely to present with ST-elevation MI (STEMI) (33.9% versus 42.5%). Women were less likely to receive guidelineindicated care when compared with men including timely reperfusion therapy for STEMI (76.8% versus 78.9%; p<0.001), and timely coronary angiography for non-STEMI (24.2% versus 36.7%; p<0.001). show benefit of an early invasive strategy in both sexes. 30 In patients with elevated biomarkers, there was a reduction in the primary endpoint of death, MI or rehospitalisation for ACS at 6 months.
A subsequent meta-analysis did lend support to the use of an early invasive strategy in women in the presence of elevated biomarkers. . 22 These data indicate that in women with elevated biomarkers, an early invasive strategy is warranted and women should therefore be undergoing angiography at a comparable rate to that of their male counterparts.
ST-elevation MI
The literature demonstrates that the benefit of early reperfusion therapy in STEMI in both sexes is unquestionable and this is reflected in current practice guidelines. 32 Nevertheless, women presenting with STEMI are less likely than men to be admitted to a hospital which has the ability to perform PCI. 33 The mortality rate of women after STEMI is higher than that of men. In one meta-analysis of 68,536 patients (27% female, n=18,555), mortality was higher in women both in hospital (RR 1.93; 95% CI [1.75-2.14];
p<0.001) and at 1 year (RR 1.58; 95% CI [1.36-1.84]; p<0.001). 34 However, women tend to be older and have more co-morbidities with a higher rate of diabetes, hypertension and high cholesterol. When these factors were taken into account, the higher 1-year mortality rate in women was no longer evident in this meta-analysis (RR 0.90; 95% CI
[0.69-1.17]; p=0.42).
Contrary to this, a recent study analysed patient-level data from 10 randomised trials and evaluated the rate of death or heart failure hospitalisation within 1 year. 35 The study evaluated 2,632 patients (22% female, n=587) and found that, despite there being no difference in the size of infarct, the adverse event rate was higher in women at 1 year:
the mortality was 3.5% versus 1.8%, p=0.01; and death or heart failure 42 This US study was specifically designed to evaluate outcomes in young patients admitted with STEMI with respect to sex and it enrolled more women than men. In accordance with other studies, women were more likely to have atypical symptoms and presented later. Of those patients deemed suitable for reperfusion therapy (women=761; men=477), the study found that women were more likely to be untreated (9% versus 4%; p=0.002) and women who did receive reperfusion experienced a longer delay to receiving therapy. 42 Mortality in STEMI is strongly associated with ischaemic time -every 30-minute delay of revascularisation increases annual mortality by 7.5%. 43 One contributor to delay is that women do not perceive heart disease as a risk to their own health. 44, 45 The delay in women seeking help appears to be irrespective of age. 40, 42 It is therefore important that public health campaigns highlight the need for all women to seek medical help promptly. Awareness should be raised among medical professionals to ensure that therapeutic pathways are optimised for women, particularly in those with an atypical presentation.
There is some evidence to suggest that PCI for women presenting with 
Stable Angina
Women are also less likely to receive optimal medical therapy for stable angina compared with men. One observational study evaluated 3,779 patients (42% female) from the Euro Heart Survey. 47 55 The adverse event rate (death, MI or target vessel revascularisation) was 12% at 1 year and 15% at 2 years. These data were compared with male patients enrolled into the SPIRIT V study and once again female patients had a longer delay to therapy.
The total referral time for coronary intervention in women was 4 days longer than that for men (p=0.0003). This may be attributed to the fact that women were more likely to have atypical angina (9% versus 6%) or indeed no chest pain (17% versus 13%) compared with men. 
Complex Percutaneous Coronary Intervention
The WIN-DES collaboration has published data demonstrating the safety and efficacy of the use of contemporary DES in 4,629 women treated for complex CAD (defined as total stent length >30 mm, two or more stents implanted, two or more lesions treated or bifurcation lesion). 56 Compared with non-complex PCI, women who had complex PCI had a higher 3-year risk of major adverse cardiac events (MACE) 
Left Main Stem Percutaneous Coronary Intervention
Disease of the left main stem (LMS) merits specific attention as revascularisation confers prognostic benefits over and above medical therapy alone. Although CABG is the gold standard, recent trials have supported the concept of PCI as a revascularisation modality for patients without a heavy burden of concomitant disease indicated by a low or intermediate SYNTAX score. 57 The outcome of PCI for LMS disease is dependent on the complexity of disease. Lesions that involve the bifurcation are subject to a higher rate of adverse events, driven mainly by the need for repeat revascularisation. 58 Women may be more likely than men to have disease at the ostium of the LMS. 59 Studies have shown that PCI for ostial LMS disease has a low rate of MACE not significantly different to the results after CABG. A recent analysis was undertaken to explore this further. 64 Investigators
showed that compared with men, women in the EXCEL trial were older, had a higher rate of hypertension, hyperlipidaemia and diabetes and there were fewer smokers. However, they also had lower coronary anatomic burden and complexity of disease (mean SYNTAX score 24.2 versus 27.2; p<0.001). On multivariate analysis, sex was not an independent predictor of the primary endpoint at 3 years (HR 1.10; 95% CI [0.82-1.48]; p=0.53). However, women treated with PCI had a higher rate of peri-procedural MI compared with men and the authors concluded that sex is an important factor to be considered and that further studies are required to determine the optimal revascularisation modality for women with this type of complex coronary artery disease.
Peri-procedural Complications
A major concern has been that women undergoing PCI have been Additional large randomised studies have also supported the use of a radial approach in reducing vascular complications and bleeding. 70, 71 One of these, the MATRIX trial, enrolled 8,404 patients (26.7% women) and specifically evaluated the impact of sex. 72 After adjustment, the overall adverse event rate was not significantly different for men versus women, however women still had an overall higher risk of access-site compared with the use of a femoral approach. Notably, although the radial approach was successful in the majority, the crossover rate for those randomised to a radial approach was higher in women than in men (7.6% versus 5.2%).
Conclusion
In contemporary PCI practice, there remains a disparity between the outcomes of women versus men, with women having significantly worse outcomes and a higher mortality. The causes are multifactorial and relate to differences in health-seeking behaviour as well as suboptimal medical therapy. Women are less likely to undergo cardiac catheterisation and revascularisation; are not treated as quickly as men; and are less likely to receive optimal pharmacotherapy.
There is no data to suggest that women benefit any less than men from guideline-recommended primary and secondary prevention cardiovascular medication and revascularisation. Medical professionals need to ensure that the management of women is not biased by a perception of increased risk, such as bleeding, which might potentially deny women from receiving evidence-based therapies. Future studies should focus on evaluating health behaviours, patterns of disease and clinical outcomes, in a sex-specific way.
